ID
TEVA icon

Integral Derivatives’s Teva Pharmaceuticals TEVA Stock Holding History

Integral Derivatives’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$461K Sell
27,000
-90,400
-77% -$1.77M 0.01% 403
2017
Q4 		$2.23M Buy
117,400
+34,900
+42% +$525K 0.04% 264
2017
Q3 		$1.45M Sell
82,500
-36,800
-31% -$828K 0.03% 391
2017
Q2 		$3.96M Buy
119,300
+62,900
+112% +$1.95M 0.08% 147
2017
Q1 		$1.81M Buy
56,400
+12,200
+28% +$416K 0.03% 340
2016
Q4 		$1.6M Buy
44,200
+28,200
+176% +$1.13M 0.03% 374
2016
Q3 		$736K Buy
16,000
+3,700
+30% +$193K 0.02% 514
2016
Q2 		$618K Sell
12,300
-28,900
-70% -$1.54M 0.01% 547
2016
Q1 		$2.21M Buy
41,200
+24,800
+151% +$1.46M 0.07% 199
2015
Q4 		$1.08M Buy
16,400
+10,600
+183% +$655K 0.03% 438
2015
Q3 		$327K Sell
5,800
-31,700
-85% -$2.06M 0.01% 831
2015
Q2 		$2.22M Buy
37,500
+16,100
+75% +$993K 0.06% 292
2015
Q1 		$1.33M Buy
21,400
+13,000
+155% +$756K 0.03% 419
2014
Q4 		$483K Sell
8,400
-53,600
-86% -$2.99M 0.01% 926
2014
Q3 		$3.33M Buy
62,000
+48,200
+349% +$2.55M 0.06% 300
2014
Q2 		$723K Sell
13,800
-25,200
-65% -$1.29M 0.01% 803
2014
Q1 		$2.06M Buy
39,000
+18,800
+93% +$869K 0.04% 400
2013
Q4 		$810K Buy
+20,200
New +$795K 0.01% 861

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Integral Derivatives's TEVA Position: Q2 2017 in Review

Integral Derivatives sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 32,601 shares — an estimated $1.01M sold.

Integral Derivatives first reported a position in TEVA in Q4 2013 and held it in 8 quarters. The position peaked at $2.54M in Q4 2016. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Integral Derivatives reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Integral Derivatives sold 32,601 Teva Pharmaceuticals shares in Q2 2017, an estimated $1.01M.
  • Integral Derivatives first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • Integral Derivatives's Teva Pharmaceuticals position peaked at $2.54M in Q4 2016.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.